Jaguar Health to Reveal Initial Findings on Crofelemer for MVID and SBS-IF

Jaguar Health, Inc. plans an investor webcast on April 30, 2025, to discuss initial results from a proof-of-concept study on crofelemer. This plant-based drug targets microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF), both rare conditions with significant medical needs. The announcement follows Dr. Mohamad Miqdady’s presentation at the ELITE PED-GI Congress in Abu Dhabi.

The webcast will feature key experts, including Dr. Miqdady and Dr. Christos Tzivinikos, sharing insights into disease progression and quality of life impacts. Current POC trials backed by Jaguar span the US, EU, and MENA regions. These findings could lead to expedited regulatory pathways for crofelemer, offering hope for early patient access in certain EU regions.